MEDNAX Inc (NYSE:MD) Stock Holdings Lifted by Prudential PLC

Prudential PLC lifted its position in MEDNAX Inc (NYSE:MD) by 15.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 553,200 shares of the company’s stock after acquiring an additional 74,700 shares during the period. Prudential PLC owned about 0.66% of MEDNAX worth $13,957,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Bremer Bank National Association acquired a new position in MEDNAX during the 1st quarter worth about $30,000. Meeder Asset Management Inc. purchased a new stake in MEDNAX during the 2nd quarter worth about $36,000. US Bancorp DE lifted its holdings in MEDNAX by 38.5% during the 2nd quarter. US Bancorp DE now owns 5,657 shares of the company’s stock worth $142,000 after purchasing an additional 1,572 shares in the last quarter. ETF Managers Group LLC increased its stake in MEDNAX by 166.0% in the 2nd quarter. ETF Managers Group LLC now owns 6,845 shares of the company’s stock worth $168,000 after acquiring an additional 4,272 shares during the last quarter. Finally, Machina Capital S.A.S. bought a new position in MEDNAX in the 2nd quarter worth about $180,000. 92.26% of the stock is currently owned by institutional investors and hedge funds.

In other MEDNAX news, Director Michael Fernandez acquired 64,242 shares of the company’s stock in a transaction on Thursday, August 8th. The stock was acquired at an average price of $21.68 per share, for a total transaction of $1,392,766.56. Following the acquisition, the director now owns 164,530 shares in the company, valued at approximately $3,567,010.40. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Md Pascal J. Goldschmidt sold 5,000 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $20.81, for a total value of $104,050.00. Following the completion of the sale, the director now owns 15,821 shares of the company’s stock, valued at approximately $329,235.01. The disclosure for this sale can be found here. 3.40% of the stock is owned by company insiders.

NYSE MD traded down $0.21 during trading on Tuesday, reaching $22.41. The company’s stock had a trading volume of 13,144 shares, compared to its average volume of 1,125,762. The stock has a market capitalization of $1.88 billion, a PE ratio of 6.54, a P/E/G ratio of 0.87 and a beta of 0.73. The company has a debt-to-equity ratio of 0.79, a current ratio of 2.23 and a quick ratio of 2.23. The firm has a fifty day moving average of $22.03 and a 200 day moving average of $25.18. MEDNAX Inc has a one year low of $19.93 and a one year high of $47.32.

MEDNAX (NYSE:MD) last announced its quarterly earnings data on Thursday, August 1st. The company reported $0.89 EPS for the quarter, beating the consensus estimate of $0.78 by $0.11. MEDNAX had a positive return on equity of 9.34% and a negative net margin of 3.53%. The firm had revenue of $868.31 million for the quarter, compared to analyst estimates of $868.71 million. During the same period in the prior year, the company earned $1.07 EPS. The company’s revenue was up .4% on a year-over-year basis. Research analysts expect that MEDNAX Inc will post 3.04 earnings per share for the current fiscal year.

A number of equities analysts have weighed in on the company. Credit Suisse Group decreased their target price on MEDNAX from $30.00 to $28.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 27th. Zacks Investment Research lowered MEDNAX from a “hold” rating to a “sell” rating and set a $26.00 target price on the stock. in a research note on Wednesday, July 3rd. Mizuho decreased their target price on MEDNAX from $26.00 to $24.00 and set a “neutral” rating on the stock in a research note on Friday, August 2nd. Bank of America lowered MEDNAX from a “neutral” rating to an “underperform” rating and set a $19.00 target price on the stock. in a research note on Friday, September 6th. Finally, BMO Capital Markets decreased their target price on MEDNAX from $32.00 to $25.00 and set a “market perform” rating on the stock in a research note on Monday, August 5th. Four equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $28.30.

MEDNAX Company Profile

MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care services; and acute and chronic pain management services.

Recommended Story: Key terms to understand channel trading

Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MEDNAX Inc (NYSE:MD).

Institutional Ownership by Quarter for MEDNAX (NYSE:MD)

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.